ReviewCureus2024
Treatment of Atopic Dermatitis in Children.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Rational Allergy Practice Guidelines by the Indian Academy of Pediatrics (IAP) and IAP-Allergy and Applied Immunology Chapter.Indian pediatrics · 2026Guideline
- Effectiveness of melatonin supplementation for improving sleep quality and disease severity in children with atopic dermatitis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Initial Management of Infantile Atopic Dermatitis in Primary Care Settings and Predictors of Topical Steroid Potency Escalation.Pediatric dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), also called eczema, is a common inflammatory skin condition that causes itchy lesions and is widespread globally, especially in wealthy countries. It is the most prevalent skin disorder among children. A small percentage of children's eczema persists into adulthood, and a few of them exhibit a severe form of the condition. The development of AD is influenced by immune, environmental, and genetic factors; mutations in the filaggrin gene and a family history of atopy are regarded as risk factors that cause a hyperimmune response, which in turn increases the production of interleukin-13 and interleukin-4. As a result, the skin barrier is compromised, the T-helper 2 immune response is subsequently triggered, and atopic dermatitis develops. Diagnosing and treating AD are mostly dependent on primary care physicians. Nonetheless, treating AD is still challenging, and most pediatricians send even patients with mild eczema to dermatologists for management. To conduct this review, we posed the central question, 'How to treat atopic dermatitis in children?' utilizing 'atopic dermatitis in children: what is the best treatment?' as the primary keywords. A comprehensive search strategy was employed, incorporating reputable databases such as PubMed, Google Scholar, and Elsevier. The inclusion criteria were set to encompass articles published in the 21st century; however, some cross-references were from the 20th century, focusing exclusively on pediatric populations worldwide. We exclusively considered articles within the realm of pediatrics to ensure relevance to our target audience, pediatricians. The overarching objective of this review article is to elucidate the challenges encountered by pediatricians in managing even mild cases of AD and to delineate the impact on the daily lives of children and caregivers. Furthermore, this article seeks to explore the spectrum of available treatments, providing valuable insights for primary care providers to enhance the efficacy of AD management in pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.